›› 2017, Vol. 44 ›› Issue (11): 3372-3378.doi: 10.16431/j.cnki.1671-7236.2017.11.037

Previous Articles     Next Articles

Study on Acute Toxicity and Sub-chronic Toxicity of the Extract of Rehmannia glutinosa

LIU Jia1,2, LI Qiang1, GUO Li2, LI Guo-hui1, ZHAO Xing-hua1, LIU Jing1, HE Xin1   

  1. 1. College of Veterinary Medicine, Hebei Agricultural University, Baoding 071000, China;
    2. Baoding Jinong Animal Pharmaceutical Co., Ltd., Baoding 071000, China
  • Received:2017-03-11 Online:2017-11-20 Published:2017-11-21

Abstract:

The purpose of this experiment was to study the acute toxicity and long-term sub-chronic toxicity of the extract of Rehmannia glutinosa in mice, evaluate the clinical safety of medication and provide theoretical basis for clinical application. Mice were chosen to measure the median lethal dose (LD50) and maximal tolerance dose (MTD). In the sub-chronic toxicity test, 80 SD rats were divided into four groups:Low dose, middle dose, high dose test groups with the extract of Rehmannia glutinosa and control group with normal saline for 30 d. On the 31th day, the rats were killed and the blood routine index, biochemistry index and the organ coefficient were measured. The MTD was 61.54 g/kg, according to the judgmental standard of the acute toxicity, the extract of Rehmannia glutinosa was safe. The sub-chronic toxicity test results showed that there were no significant difference in body weight and blood chemistry indexes and organ coefficient among the four groups (P>0.05) and there were no pathological change because of the medication. The result indicated that the extract of Rehmannia glutinosa was no acute toxicity under the condition of this test according to acute toxicity classification standard of exogenous by WTO, and it was no sub-chronic toxicity too, which suggested the extract had a good clinical safety.

Key words: extract of Rehmannia glutinosa; acute toxicity; sub-chronic toxicity; safety

CLC Number: